Figure 1 (colour required for print)
Although the exact trigger of MS is unknown, clues regarding its aetiology have been derived from pathological and imaging studies. It is clear that following a central or peripheral activating event, infiltration of peripheral immune cells occurs either across a leaky bloodbrain barrier (BBB), across the blood-CSF barrier at the choroid plexus or via the subarachnoid space [13] . Subsequent parenchymal damage manifests as gadoliniumenhancing lesions on MRI and correlate reasonably with episodic clinical disease activity, termed relapses [14, 15] . Autoreactive T cells, directed against myelin epitopes, are thought to play a central role in driving immune-mediated damage in MS, leading to demyelination and underlying axonal damage. However, whether this process represents a primary initiating event, or exacerbates an earlier, more generalised inflammatory response, is unclear.
Clonally-expanded somatic mtDNA deletions have been found in respiratory-deficient neurons of secondary-progressive MS patients [16] , but as with other neurodegenerative diseases that also harbour increased neuronal mtDNA mutations [6] , the timing of these genetic changes and their effect on downstream processes is unclear. Studies to date interrogating the role of specific inherited mtDNA single nucleotide variants have been limited by small sample sizes and the majority have focussed on LHON mtDNA mutations (reviewed in [17] ), though reports of an MS-like syndrome in patients with mutations in nuclear-encoded mitochondrial genes, such as OPA1 [18] [19] [20] and POLG [21] , have also been described. Following an earlier effort to understand the role of mtDNA variation in MS and other common human disease [22] , a recent large study has evaluated the association between MS and mitochondrial SNPs using >7000 MS cases and >14000 controls from 7 countries [23] . No single mtDNA variant was associated with MS risk but an association between mitochondrial haplogroups J, T and JT with MS risk was reported in a discovery cohort, though this was not able to be replicated in an independent cohort. A similar association between haplogroup J and T carriers and MS risk has been described in smaller cohorts [24, 25] and is of particularly interest given that some of the single nucleotide polymorphism (SNP) that define these haplogroups encode subunits of mitochondrial complex 1.
Mitochondrial haplogroups represent groupings of shared polymorphisms, differentiated through sequential addition of single nucleotide variants over the course of human history [26] . It is difficult to establish the functional consequence of each individual SNP within each haplogroup, due to the challenge of defining 'haplogroup-defining' SNPs and because some variants are in almost complete linkage disequilibrium with each other. However, evidence from cytoplasmic hybrid (cybrid) cell lines, in which mitochondrial variants are compared against the same nuclear background, suggest that different mitochondrial haplogroups can alter inflammatory responses [27] [28] [29] . Further work is required to clarify the pathways involved in modulating this response, and how this translates to clinical differences in MS risk and disease progression for patients with each mitochondria haplogroup.
Accumulation of mtDNA damage, either as a primary or secondary event, can affect the transcription and assembly of respiratory chain subunits, resulting in defects in ATP production. Mitochondrial respiratory chain complex I activity is reduced in chronic active MS lesions [30] and both complex I and III gene transcripts are decreased in non-lesional motor cortex of MS patients when compared to healthy controls [31] . The numbers of gene transcripts for nuclear-encoded respiratory chain complex I, II, IV and V subunits were also found to be reduced in this group, though the activity of complex IV was unaffected [31] . In normal-appearing grey matter of MS patients, mtDNA abundance (copy number) is increased, which may be a mechanism to compensate for reduced complex transcripts, by providing sufficient mtDNA-encoded subunits to allow for complex assembly [32] .
Alteration in respiratory chain function may be context-dependent, requiring accompanying insults to manifest as a biochemical defect [33] . A detectable loss of the mtDNA-encoded complex IV catalytic subunit (COX-1) is seen in pattern III MS lesions but not in acute pattern II lesions [34, 35] Pattern III lesions are seen in fulminant disease and aggressive MS subtypes and are associated with hypoxia-like tissue injury [35] , which may provide the additional insult required to drive damage above a biochemical threshold [33] . With inhibition of oxidative phosphorylation, electron flux is diverted to generate reactive oxygen (ROS) and reactive nitrogen species (RNS), causing further damage to respiratory chain subunits, resulting in a self-perpetuating cycle that is especially damaging to vulnerable, demyelinated axons [36, 37] . Indeed, oxidative stress, resulting from an imbalance between the cell's production of ROS and ability to compensate via antioxidant activity, may be a key driver for cell loss in acute lesions. In vitro oligodendrocytes are more sensitive to reactive oxidative and nitrative species and this may account for selective loss of oligodendrocyte in demyelinating lesions [38] .
Neuronal cells are particularly sensitive to disruption to oxidative phosphorylation due to their reliance on large amounts of ATP to maintain their membrane potential, via the Na+/K+ ATPase pump. Membrane ATPase dysfunction is thought to occur following demyelination where ATP production is inadequate, and results in increased intracellular sodium concentrations [39, 40] . Axons compensate by upregulating production and redistribution of sodium channels along the axonal membrane and by reversing the Na-Ca exchanger which expels sodium at the expense of increasing calcium influx [41] . In acute demyelinating lesions, accumulation of axonal calcium activates calcium-dependent cysteine protesases which disrupt cytoskeletal processes and lead to axonal injury [40, 41] . These ionic imbalances promote a self-perpetuating cycle in which calcium directly modulates expression of sodium channels [42] , further aggravating Na + /K + ATPase dysfunction. Increased sodium loading within the axon also drives axonal release of glutamate by reversing the action of sodium-dependent transporters [43] . The resulting excess glutamate concentration in the white matter cause myelin and oligodendrocyte toxicity via both direct and indirect pathways, involving AMPA and NMDA receptors signalling. AMPA activation leads to axonal damage by increasing mitochondrial calcium concentration via the mitochondrial permeability transition pore [44] [45] [46] , as well as by triggering ERK-mediated oligodenderocyte apoptosis [47] . Similarly, NMDA stimulation induces mitochondrial toxicity by increasing calcium levels and decreasing levels of superoxide dismutase 2 (SOD-2), mitochondrial membrane potential and ATP production [48] . These processes may be amplified in neurons with underlying sub-clinical mitochondrial defects, as noted in carriers of primary mitochondrial disorders.
Mitochondrial disease and MS: LHON and LHON-MS
Leber's hereditary optic neuropathy (LHON) is a maternally inherited mitochondrial disease characterised by bilateral, subacute visual loss in early adult life [49] . Three common pathogenic mitochondrial DNA variants account for 90-95% of LHON -m.3460G>A, m.11778G>A, m.14484T>C -and these are found in genes encoding subunits of respiratory chain complex I. Although retinal ganglion cells are preferentially affected, leading to optic nerve degeneration, additional extraocular abnormalities have been described in LHON pedigrees. These include non-neurological (cardiac arrhythmias, myopathy) as well as neurological abnormalities (tremor, dementia, movement disorders, peripheral neuropathy, and a multiple sclerosis-like presentation) [49] . [65, 68] . An interaction between the two diseases would account for these differences, and may be additive or synergistic (Fig. 1) . The presence of mtDNA LHON mutations as a background to MS may result in an atypical optic neuritis (which is severe, painless and irreversible) or alternatively, the presence of MS or its risk factors may precipitate LHON in patients who would otherwise have been asymptomatic or compound damage in tissues affected by both diseases.
Interaction between mtDNA mutations and MS at a molecular level may converge on shared pathways of oxidative damage and cell death (Fig. 1) . Complex 1 dysfunction caused by LHON mtDNA mutations results in decreased ATP synthesis, increased ROS production and impairments in glutamate transport leading to retinal ganglion cell dysfunction and apoptosis [69, 70] . Similar impairments are seen in demyelination and neurodegeneration in MS, whereby mitochondrial damage leads to respiratory chain complex dysfunction and glutamate excitotoxicity. Therefore, in patients with inherited (e.g. mtDNA) or acquired (neuroinflammation-induced mitochondrial dysfunction) defects in these overlapping pathways, there may be an increased likelihood of apoptosis, resulting in a more severe disease phenotype. This overlap gives hope for the treatment of multiple sclerosis with mitochondrial-targeted therapeutics that specifically address these shared pathways.
Examples include mitoQ, a mitochondria-targeted antioxidant, shown to reduce inflammation and neuronal loss in spinal cord of EAE mouse models [71, 72] , and the enhancement of mtDNA repair processes in oligodendrocytes to protect against ROS and cytokine-induced apoptosis [73, 74] . Future work is required to establish the timing of drug delivery relative to the initial insult; it is likely that therapeutic benefit can only be achieved if drugs are administered prior to irreversible cell processes, such as apoptosis. Furthermore, specific delivery of these compounds to their desired site of action within the cell remains a challenge and will ultimately require trials with human subjects to clarify issues of dosing and safety.
Conclusion
Characterising 
